PDGFRA and neoplasm: They hypothesize that the H3.3-G34R/V mutation may become dispensable following the acquisition of PDGFRA overexpression and that PDGFRA activates downstream MAP/ERK signaling, increasing the clonogenicity and expansion of the astrocytic compartment of the tumor (at the expense of the neuronal components) [57].